MA55625A - Compositions et méthodes d'administration de produits thérapeutiques - Google Patents
Compositions et méthodes d'administration de produits thérapeutiquesInfo
- Publication number
- MA55625A MA55625A MA055625A MA55625A MA55625A MA 55625 A MA55625 A MA 55625A MA 055625 A MA055625 A MA 055625A MA 55625 A MA55625 A MA 55625A MA 55625 A MA55625 A MA 55625A
- Authority
- MA
- Morocco
- Prior art keywords
- administration
- compositions
- methods
- therapeutic products
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833447P | 2019-04-12 | 2019-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55625A true MA55625A (fr) | 2022-02-16 |
Family
ID=72750879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055625A MA55625A (fr) | 2019-04-12 | 2020-04-10 | Compositions et méthodes d'administration de produits thérapeutiques |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220168449A1 (fr) |
EP (1) | EP3952924A4 (fr) |
JP (1) | JP2022526425A (fr) |
KR (1) | KR20220007601A (fr) |
CN (1) | CN114430684A (fr) |
AU (1) | AU2020272980A1 (fr) |
BR (1) | BR112021020421A2 (fr) |
CA (1) | CA3136646A1 (fr) |
CL (1) | CL2021002635A1 (fr) |
CO (1) | CO2021013548A2 (fr) |
EA (1) | EA202192801A1 (fr) |
IL (1) | IL287137A (fr) |
MA (1) | MA55625A (fr) |
MX (1) | MX2021012527A (fr) |
SG (1) | SG11202111195VA (fr) |
TW (1) | TW202104596A (fr) |
WO (1) | WO2020210633A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020068990A1 (fr) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Compositions de virus adéno-associé pour une thérapie génique ciblée |
EP4291654A2 (fr) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de superoxyde dismutase 1 (sod1) et procédés d'utilisation correspondants pour traiter ou prévenir des maladies neurodégénératives associées à la superoxyde dismutase 1 (sod1) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007044627A2 (fr) * | 2005-10-06 | 2007-04-19 | Sloan Kettering Institute For Cancer Research | Compositions et methodes d'administration d'arn interferant |
SI2029742T1 (sl) * | 2006-06-07 | 2016-11-30 | Genzyme Corporation | Genska terapija amiotrofične lateralne skleroze in drugih motenj hrbtenjače |
EP2158322B1 (fr) * | 2007-06-06 | 2017-05-03 | Genzyme Corporation | Thérapie génique pour les maladies de stockage lysosomal |
MX356669B (es) * | 2009-05-02 | 2018-06-08 | Genzyme Corp | Terapia genica para trastornos neurodegenerativos. |
BR112015027336A2 (pt) * | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
RU2018128780A (ru) * | 2013-07-26 | 2018-12-05 | Юниверсити Оф Айова Рисерч Фаундейшн | Способы и композиции для лечения болезней мозга |
RU2749882C2 (ru) * | 2014-11-14 | 2021-06-18 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
PL3411484T3 (pl) * | 2016-02-05 | 2024-02-19 | Emory University | Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego |
IL266862B2 (en) * | 2016-12-01 | 2024-01-01 | Sangamo Therapeutics Inc | Tau modulators and methods and preparations for their administration |
US20200040061A1 (en) * | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
KR20200023280A (ko) * | 2017-05-11 | 2020-03-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신경 세로이드 지질갈색소증에 대한 유전자 요법 |
WO2018213786A1 (fr) * | 2017-05-19 | 2018-11-22 | Encoded Therapeutics, Inc. | Éléments régulateurs à haute activité |
JP7432621B2 (ja) * | 2019-05-29 | 2024-02-16 | エンコーデッド セラピューティクス, インコーポレイテッド | 選択的遺伝子調節のための組成物および方法 |
-
2020
- 2020-04-10 US US17/602,936 patent/US20220168449A1/en active Pending
- 2020-04-10 TW TW109112217A patent/TW202104596A/zh unknown
- 2020-04-10 KR KR1020217035766A patent/KR20220007601A/ko unknown
- 2020-04-10 SG SG11202111195VA patent/SG11202111195VA/en unknown
- 2020-04-10 EP EP20787609.5A patent/EP3952924A4/fr active Pending
- 2020-04-10 AU AU2020272980A patent/AU2020272980A1/en not_active Abandoned
- 2020-04-10 BR BR112021020421A patent/BR112021020421A2/pt not_active Application Discontinuation
- 2020-04-10 CA CA3136646A patent/CA3136646A1/fr active Pending
- 2020-04-10 MA MA055625A patent/MA55625A/fr unknown
- 2020-04-10 WO PCT/US2020/027682 patent/WO2020210633A1/fr unknown
- 2020-04-10 JP JP2021559784A patent/JP2022526425A/ja active Pending
- 2020-04-10 MX MX2021012527A patent/MX2021012527A/es unknown
- 2020-04-10 CN CN202080042139.6A patent/CN114430684A/zh active Pending
- 2020-04-10 EA EA202192801A patent/EA202192801A1/ru unknown
-
2021
- 2021-10-08 CL CL2021002635A patent/CL2021002635A1/es unknown
- 2021-10-10 IL IL287137A patent/IL287137A/en unknown
- 2021-10-12 CO CONC2021/0013548A patent/CO2021013548A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20220168449A1 (en) | 2022-06-02 |
BR112021020421A2 (pt) | 2021-12-21 |
CL2021002635A1 (es) | 2022-07-15 |
EA202192801A1 (ru) | 2022-02-24 |
IL287137A (en) | 2021-12-01 |
EP3952924A1 (fr) | 2022-02-16 |
TW202104596A (zh) | 2021-02-01 |
CA3136646A1 (fr) | 2020-10-15 |
AU2020272980A1 (en) | 2021-11-04 |
WO2020210633A8 (fr) | 2021-09-30 |
WO2020210633A1 (fr) | 2020-10-15 |
KR20220007601A (ko) | 2022-01-18 |
SG11202111195VA (en) | 2021-11-29 |
CN114430684A (zh) | 2022-05-03 |
JP2022526425A (ja) | 2022-05-24 |
MX2021012527A (es) | 2022-01-06 |
CO2021013548A2 (es) | 2022-01-28 |
EP3952924A4 (fr) | 2023-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56541A (fr) | Plateformes, compositions et méthodes d'administration de composés thérapeutiques | |
ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
MA43172A (fr) | Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications | |
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
IL288375A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
IL273125A (en) | Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them | |
EP3621593A4 (fr) | Compositions pharmaceutiques et méthodes de traitement de maladies cardiovasculaires | |
IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
MA55625A (fr) | Compositions et méthodes d'administration de produits thérapeutiques | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MA55291A (fr) | Procédé de fabrication d'extraits bactériens stables et leur utilisation en tant que produits pharmaceutiques | |
GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB202010464D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
EP4058017A4 (fr) | Formulations médicamenteuses et méthodes de traitement de troubles métaboliques | |
MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
MA50526A (fr) | Cocristaux, compositions pharmaceutiques de ceux-ci, et méthodes de traitement les impliquant | |
MY194044A (en) | Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products | |
MA52587A (fr) | Composés d'azabenzimidazole et produit pharmaceutique | |
IL286416A (en) | Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration | |
IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
EP4013401A4 (fr) | Articles et modes d'administration d'agents thérapeutiques | |
EA202191378A1 (ru) | Активные сложноэфирные производные тестостерона, их композиции и применения | |
MA49092A (fr) | Compositions et procédés pour la préparation d'acides , -insaturés |